Analysis Datasets for Forum for Collaborative HIV Research Drug Resistance Initiative

The RESIST trials are international randomized studies of ritonavir boosted protease inhibitor based treatment of the HIV-1 infections of three class experienced patients. All patients were screened with genotypic testing and a random sample was assayed phenotypically. Demographic, Disease History, Treatment, and Response files will accompany Resistance files in the analysis datasets.

All files will be structured with linking fields of trial number (1182.12 or 1182.48) and patient number.

Content of individual files:

Demographic:
Country, Race, Sex, Age, Infection Risk Factors, Height, Weight

Disease History
First Tested Positive, Prior Treatment, Prior AIDS, Hepatitis B status, Hepatitis C status, Ongoing AIDS

Treatment
Treatment at screening, Pre-selected Optimized Background and Control Protease Inhibitor, Trial Treatment, Changes/Interruptions of Trial Treatment

Response
HIV RNA by visit, CD4 count by visit, Virologic Response by 3 definitions: > 1 log change from baseline, <400 copies/ml, <50 copies/ml (response at week 8, response at week 24, time to failure), Incident AIDS progression or death, Disposition.

Genotype 1
For each specimen: source (VIRCO or Bayer), clade, Reverse Transcriptase and Protease Amino Acids (reported as deviations from reference sequence)

Genotype 2
For each specimen: fasta files of aligned nucleotide sequence for Reverse Transcriptase and for Protease.

Phenotype
VIRCO antivirogram report of IC50 fold change for NRTIs, NNRTIs, and PIs licensed at the time of trial enrollment, as well as for Tipranavir.